|
UK's NICE rejects Novartis asthma drug in change of tack
Chicago Tribune LONDON (Reuters) – Britain's health cost-effectiveness watchdog NICE plans to recommend against the use of Novartis's severe asthma drug Xolair, or omalizumab, after earlier endorsing it for adults only. The National Institute for Health and Clinical … |
View full post on asthma – Google News